In mouse tumor models (melanoma and colorectal cancer), several groups have clearly shown that surrogate anti-CTLA-4 antibody-mediated anti-tumor efficacy is dependent on Fc effector functions and correlate with depletion of tumor-infiltrating Tregs (10, 30, 56) (Figure 1A). The gene discussed is CTLA4; the disease is melanoma.